Targaxan rifaximin regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of episodes of overt hepatic encephalopathy (HE) in adults -- its approved indication in the EU. In December, the agency said it needed more information on the non-absorbed, broad-spectrum antibiotic before it could make a decision (see BioCentury, Dec. 9, 2013). NICE concluded that the most plausible incremental cost effectiveness ratio (ICER) was likely to be close to the top end of the £20,000-£30,000 range normally considered cost effective. ...